DANAHER CORPDHR
時価総額
$1628.2億
PER
ライフサイエンス機器・試薬の大手。質量分析装置やレーザー走査顕微鏡、抗体試薬などのプロテオミクス製品を展開。2023年12月に主要プロテオミクス企業を約56億ドルで買収。北米・欧州・アジア中心に約60カ国で展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Sales | - | - | - | - | - | - | - | - | - | 17,911 | 22,284 | 29,453 | 31,471 | 23,890 | 23,875 |
| Cost of sales | 6,576 | 7,914 | 8,846 | 9,160 | 9,471 | 9,801 | 7,548 | 8,137 | 8,786 | 7,927 | 9,809 | 11,501 | 12,522 | 9,856 | 9,669 |
| Gross profit | 6,627 | 8,177 | 9,414 | 9,958 | 10,443 | 10,763 | 9,335 | 10,193 | 11,107 | 9,984 | 12,475 | 17,952 | 18,949 | 14,034 | 14,206 |
| Selling, general and administrative expenses | 3,674 | 4,608 | 5,181 | 5,433 | 5,697 | 6,054 | 5,609 | 6,043 | 6,472 | 5,588 | 6,896 | 8,198 | 8,516 | 7,329 | 7,759 |
| Research and development expenses | 809 | 1,019 | 1,138 | 1,250 | 1,314 | 1,239 | 975 | 1,129 | 1,231 | 1,126 | 1,348 | 1,742 | 1,745 | 1,503 | 1,584 |
| Operating profit | 2,166 | 2,617 | 3,165 | 3,275 | 3,431 | 3,469 | 2,751 | 3,021 | 3,404 | 3,269 | 4,231 | 7,465 | 8,688 | 5,202 | 4,863 |
| Other income (expense), net | - | - | - | - | - | - | - | - | - | - | 39 | 456 | -226 | -175 | -56 |
| Interest expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 278 |
| Interest income | 6 | 5 | 3 | 6 | 17 | 5 | 0 | 8 | 9 | 139 | 71 | 11 | 41 | 303 | 117 |
| Earnings from continuing operations before income taxes | - | 2,448 | 3,011 | 3,566 | 3,482 | 3,324 | 2,611 | 2,939 | 3,293 | 3,305 | 4,495 | 7,598 | 8,292 | 5,044 | 4,646 |
| Income taxes | 550 | 513 | 712 | 871 | 883 | 725 | 458 | 469 | 642 | 873 | 849 | 1,251 | 1,083 | 823 | 747 |
| Net earnings from continuing operations | - | 1,935 | 2,299 | 2,695 | 2,598 | 2,599 | 2,153 | 2,470 | 2,651 | 2,432 | 3,646 | 6,347 | 7,209 | 4,221 | 3,899 |
| Earnings from discontinued operations, net of income taxes | - | - | - | - | - | - | - | - | - | 576 | - | 86 | - | 543 | - |
| Net earnings | 1,793 | 2,172 | 2,392 | 2,695 | 2,598 | 3,357 | 2,554 | 2,492 | 2,651 | 3,008 | 3,646 | 6,433 | 7,209 | 4,764 | 3,899 |
| Mandatory convertible preferred stock dividends | - | - | - | - | - | - | - | - | - | 68 | 136 | 164 | 106 | 21 | - |
| Net earnings attributable to common stockholders | - | - | - | - | - | - | - | - | - | 2,940 | 3,510 | 6,269 | 7,103 | 4,743 | 3,899 |
| Income (Loss) from Continuing Operations, Per Basic Share | - | 2.86 | 3.32 | 3.87 | 3.7 | 3.72 | 3.12 | 3.55 | 3.78 | 3.31 | 4.97 | 8.65 | 9.8 | 5.7 | 5.33 |
| Income (Loss) from Continuing Operations, Per Diluted Share | - | 2.77 | 3.23 | 3.8 | 3.63 | 3.67 | 3.08 | 3.5 | 3.74 | 3.26 | 4.89 | 8.5 | 9.66 | 5.65 | 5.29 |
| Net earnings per common share from discontinued operations, basic (in usd per share) | - | 0.35 | 0.13 | - | - | 1.09 | 0.58 | 0.03 | - | 0.81 | - | 0.12 | - | 0.74 | - |
| Net earnings per common share from discontinued operations, diluted (in usd per share) | - | 0.34 | 0.13 | - | - | 1.07 | 0.57 | 0.03 | - | 0.79 | - | 0.12 | - | 0.73 | - |
| Earnings Per Share, Basic | 2.74 | 3.21 | 3.45 | 3.87 | 3.7 | 4.81 | 3.69 | 3.58 | 3.78 | 4.11 | 4.97 | 8.77 | 9.8 | 6.44 | 5.33 |
| Earnings Per Share, Diluted | 2.64 | 3.11 | 3.36 | 3.8 | 3.63 | 4.74 | 3.65 | 3.53 | 3.74 | 4.05 | 4.89 | 8.61 | 9.66 | 6.38 | 5.29 |